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The role of SP-B1-25 peptides in lung surfactant monolayers 
exposed to gold nanoparticles  
Sheikh I. Hossaina, Neha S. Gandhib, Zak E. Hughesc, Suvash C. Sahaa* 
Lung surfactant (LS) monolayers that continuously expand and compress during breathing cycles, act as the first line barrier 
for inhaled nanoparticles. It is known that nanoparticles which adsorb to the surface of the surfactant layer facilitate the 
rearrangement of lipids and peptides at various stages of the breathing cycle. However, the structural mechanisms for this 
ability of the lipid rearrangement are not yet fully understood. Coarse-grained molecular dynamics simulations are 
performed to investigate the role of surfactant protein B (SP-B) segments (SP-B1-25) in modulating the biophysical properties 
of the surfactant monolayer in the presence of polydisperse gold nanoparticles (AuNPs) at different concentrations. Herein, 
we observe that the AuNPs significantly alter the inherent structural and dynamical properties of the monolayer and its 
components in three different breathing states. When adsorbed into the monolayer, the AuNPs inhibit the ability of the 
monolayer to recover its surface tension and other properties. The presence of SP-B1-25 in the monolayer accelerates the 
diffusion of the monolayer phospholipids, contrarily to the role of AuNPs on phospholipid diffusion. Also, the AuNPs and the 
peptides in the monolayer significantly increase their agglomeration in the presence of one another. Overall, the simulations 
predict that the presence of polydisperse AuNPs hampers the stability and biophysical functions of the LS in contrast to the 
role of the peptide. This study provides a clear view of hydrophobic peptide role on the LS monolayer at the interface along 
with the interactions and the translocation of AuNPs that could have a significant impact to assess the NPs inhalation.  
1. Introduction 
A lung surfactant (LS) layer is responsible for the cycling of lung 
volume during the respiration process. It controls the surface 
tension at the air-water interface in alveoli to prevent alveolar 
collapse and reduce the work of breathing. The LS layer is a 
mixture of saturated and unsaturated phospholipids (PLs), and 
cholesterol, which combined make up 90 wt% of the LS. Small 
amounts (~10 wt%) of surfactant proteins (SP), both hydrophilic 
(e.g. SP-A, and SP-D) and hydrophobic (e.g. SP-B, and SP-C) are 
also found in the LS.1 Hydrophobic surfactant monolayer 
associated proteins, SP-B/-C, and surfactant lipids, mainly 
dipalmitoylphosphatidylcholine (DPPC), unsaturated lipids, 
such as 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol 
(POPG), and cholesterol (neutral lipid) form a stable monolayer 
at the air-water interface of the lung alveoli and, thus, stimulate 
the gas exchange process during breathing.2 The LS monolayer 
components stabilise the monolayer, with the role of surfactant 
proteins being significant. For example, the surfactant peptide 
SP-B initiates folding of the LS by fluidizing the monolayer3, 4. 
During the LS monolayer compression (during exhalation), the 
surface tension at the interface is reduced to ~0 mN/m from the 
equilibrium surface tension ~20-25 mN/m, achieved upon 
membrane expansion (inhalation).5 The interfacial surface 
tension of the LS monolayer is responsible for determining 
much of the structural, dynamical, and biophysical 
characteristics of the surfactant layer.6 As such, it is essential to 
understand the changes inhaled species make to the structural 
and dynamical properties of the monolayer as these will, in 
turn, affect the biophysical properties of LS monolayer.  
Fine and ultrafine particles (PM2.5<2.5 µm and PM0.1<100 
nm) at high concentrations pose the greatest risk to human 
health as they rapidly and easily enter into deep area of the 
respiratory system and cause lung dysfunction.7 In an in vitro 
experiment 8 it is reported that ultrafine AuNPs (PM0.1) have 
been detected in blood and urine three months after 
exposure. There is a significant amount of literature concerning 
the possible consequences of inhaling airborne nanoparticles 
(NPs) into the lung.9-13 Most of these studies, whether 
computational or experimental, have been concentrated on the 
effects of common airborne NPs (carbon14, 15, silica16, gold12, 13, 
and others17-19) on LS monolayer. In these studies, the 
consequences of airborne NPs inhalation have been 
investigated in terms of the NPs’ size11, shape17, surface 
properties (surface charge, hydrophobicity/hydrophilicity)20, 
and concentration.10 NP surface charge significantly affects the 
translocation of the NPs in the surfactant monolayer. For 
instance, Chen et al.21 reported that an increase in the surface 
charge of NPs can reduce the translocation of the NPs in the 
surfactant monolayer. The interaction of NPs with LS 
monolayers at high surface tension can result in the formation 
of pores in LS and the aggregation of NPs.10, 11 The presence of 
NPs has also been shown to alter the structural and mechanical 
properties of LS monolayers, inducing the layer collapse at 
higher surface tensions.22 However, when investigating the 
impact of NPs concentrations on LS monolayer, almost all of the 
computational studies considered monodisperse NPs, even 
though the primary sources of airborne NPs (industrial process 
occurring in urban areas) result in a polydisperse mixture of 
NPs. Moreover, most simulations studies have overlooked the 
key role of surfactant peptides.12, 23 Experimentally, it is 
challenging to prepare the well-controlled size (high degree of 
uniformity) NPs and thus polydisperse samples of NPs are used 
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in the determination of Langmuir monolayers’ mechanical 
properties.24 An experimental study found that the broad size 
distribution of gold NPs (AuNPs) reduced the stiffness of the 
lipid layer.24 In addition, heterogeneity of NP size may influence 
the therapeutic efficacy and translocation ability of the NPs. 25  
The existing literature sufficiently explains the role of 
surfactant peptides in the LS monolayer3, 26-28; however, it is 
essential to explore the role of SP-B1-25 peptides in monolayers 
exposed to, different concentrations of, NPs. Thus, to gain a 
thorough understanding of the effect of NPs on LS monolayers 
with SP-B1-25 peptide, the impact of polydisperse NP samples 
requires more significant consideration, particularly for AuNPs. 
The vast interest of AuNPs in fields like nanomedicine and 
biotechnology29, 30, along with the inhalation of bare AuNPs 
from the environment has raised the question of potential 
health risk associated with the exposure of AuNPs.31 For 
example, gold miners have to face different lung diseases due 
to exposure to gold dust from their occupational 
circumstances.32-34 Recent experimental studies suggested that 
the inhaled NPs (engineered or environmental) may be 
responsible for lung-related diseases and AuNPs were detected 
longer times after exposure, when compared to other NPs.8, 35 
It has also been observed that the detection levels were higher 
for 5 nm (diameter) sized AuNPs compared to 30 nm (diameter) 
AuNPs, and that AuNPs with the size <10 nm (diameter) showed 
higher translocation ability than larger AuNPs.8 The 
translocation of AuNPs from the lung to other organs in animal 
models was investigated by, Yu et al.36, with AuNP aggregation 
found in the lungs and AuNPs detected 15 days after exposure. 
A study by Takenaka et al.37, used spherical AuNPs with 
diameters of 5-8 nm (diameter) to investigate the fate of the 
NPs using experimental methods. It was found that most of the 
inhaled AuNPs were retained in the lung, and only a meagre 
amount (0.03-0.06 % of lung concentrations) were transferred 
from the lung to blood circulation.  Bakshi et al.9 and Zhang et 
al.38 considered AuNPs as a model air pollutant in in vitro 
studies, predicting that the bare AuNPs disrupt routine lung 
activity, and that at high concentration (> 100 µg/mL) the 
presence of AuNPs in the lung could be the reason for the 
formation of cracks and cavities in the lung monolayer. 
Moreover, it was hypothesized that the adsorption of AuNPs 
hinders the ability of the LS to reduce the surface tension of the 
lung during compression, even in the presence of SP-B.38 All 
these experimental studies suggest that the size distribution 
and concentration of NPs can play an essential role in altering 
the intrinsic functions of the lungs, as well as the ultimate fate 
of the inhaled NPs.  
In the present study a series of coarse-grained molecular 
dynamics (CGMD) simulations were performed on the AuNPs LS 
systems to elucidate the role of peptide and AuNPs, at different 
AuNP concentrations, and on the three states of the LS 
monolayers. In our previous studies, AuNPs of uniform size (~3 
nm diameter) were simulated at different concentrations 
interacting with LS monolayers at two different surface tensions 
(relating to the inhalation and exhalation states).12, 13 However, 
AuNP samples generally exist as a polydisperse mixture, and 
such molecules are more to cytotoxic than particles with well-
defined size.39 In previous studies12, 13 the role of polydispersity 
and SP-B1-25 peptide was neglected. Therefore, in the present 
work, we intend to address the effect of the presence of SP-B1-
25 in LS monolayers exposed to polydisperse AuNPs. Hence, we 
modelled LS peptide associated monolayer systems in three 
different breathing states (I: expanded, II: compressed, and III: 
re-expanded) at varying levels of AuNP concentration (~0.19 - 
~1.53 mol% of AuNPs/lipids). The findings of this study will help 
to elucidate the molecular mechanism of the interactions 
among hydrophobic AuNPs, hydrophobic peptide, and other LS 
components, providing insights into how the inhalation of NPs 
can contribute to damage to the lungs during different 
breathing cycles (expansion, compression, and re-expansion) as 
well as the NPs transportation in LS monolayer with lipoprotein 
corona formation.  
2. Computational methods 
Lung surfactant model  
The monolayers (Fig. 1) used in the present study as a model for 
LS membranes consisted of DPPC and POPG PLs, cholesterol, 
and a segment of surfactant protein B, SP-B1-25. SP-B is a 79 
residue long hydrophobic protein with three intramolecular 
disulfide bridges40, and is capable of forming a homodimer 
through another intermolecular disulphide bond. Various SP-B 
fragments and constructs have been reported41-43 to attempt to 
decipher the structure-activity relationship of the full-length 
peptide, one such peptide SP-B1-25 (which incorporates the first 
25 residues from N-terminal) was found capable of retaining a 
substantial level of the biological properties/activities of the 
full-length SP-B.44 For example, like SP-B, SP-B1-25 enhances the 
surfactant adsorption process at the air-water interface.3, 45 
Thus, for simplicities sake, we choose to use SP-B1-25 in our 
models. SP-B1-25 in humans has the sequence FPIPL PYCWL 
CRALI KRIQA MIPKG, is a monomer peptide with strong α-helical 
content, which when surrounded by PLs, is orientated such that 
the hydrophobic portion of the peptide (residues one to eight) 
points towards the PL tails.46 The SP-B1-25 molecules were 
inserted into a lipid bilayer of DPPC:POPG:CHOL using a python 
script (INSANE47). The bilayer was then split into two 
monolayers, and each monolayer consisted of 1035 lipids and 9 
SP-B1-25 (with the N-terminus region placed close to lipid head 
groups), in a ratio of DPPC to POPG to CHOL to SP-B1-25 of 
70:30:10:1. The monolayers were aligned parallel to the XY 
plane and separated by a ~21 nm layer of 150 mM NaCl aqueous 
solution (equivalent to ~100000 CG water sites), and ~34 nm of 
vacuum, with the monolayer lipids, orienting its hydrophilic 
heads towards the water layer and hydrophobic tails towards 
the vacuum. Here, we used ~21 nm water layer, such that the 
diameter of the largest AuNP was significantly less than the 
distance between the two monolayers, ensuring that any 
artefacts due to system size were kept to a minimum. Sufficient 
Na+ beads above 150 mM NaCl were present to make the 
system charge neutral.  
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Fig. 1 Model LS monolayer initial structure at the vacuum-water interface in the presence of AuNPs (a) side view of the system with ~1.53 mol% of AuNPs/lipids, PL head group are 
shown in blue (b) CG structures of surfactant PLs, cholesterol, and SP-B1-25. In SP-B1-25, the charged CG beads are shown in red (positive) and blue (negative), while neutral beads are 
in coloured orange. 
Coarse-grained molecular dynamics simulations 
CGMD simulations using the MARTINI force field have been 
used in most previous simulation studies of LS-NP systems to 
allow the exploration of long time and length scales.48, 49 For all 
simulations in the present study, the MARTINI force field was 
used to model the surfactant monolayer components, lipids, 
water, and ions (see Fig. 1). The CG model of SP-B1-25 was 
generated by conversion of an atomistic structure of SP-B1-25 
(obtained from the protein data bank, PDB ID: 1DFW) via the 
use of the python script martinize.py from MARTINI website.50 
All-atom structures of two different sizes AuNPs (3 and 5 nm) 
with a lattice constant of 0.408 nm were obtained from 
nanoparticle builder of OpenMD51, which uses Sutton-Chen 
force field.52 In contrast to the conventional 4:1 MARTINI 
mapping, each atom of the AuNPs (887 and 3925 atoms for 3 
and 5 nm AuNPs, respectively) was mapped 1:1 to convert the 
atomistic structures to CG structures. The force field 
parameters for AuNPs beads were taken from Song et al.53, 
where each Au bead was assigned as C5-type (hydrophobic) 
interaction site53, 54 for spherical CG AuNPs. A weak harmonic 
potential for bonded interactions55, 56 was used to establish a 
connection among the CG AuNPs beads. 
All CGMD  simulations were performed using a protocol 
reported previously.12 For the non-bonded interactions, a cutoff 
of 1.2 nm was used, with the Coulomb potential smoothly 
shifted to 0 between 0 and 1.2 nm, and the Lennard-Jones 
potential was shifted to 0 between 0.9 and 1.2 nm. Periodic 
boundary conditions were employed in all directions. All the 
systems were equilibrated for 100 ns and production runs were 
performed for 3 μs, with a time step of 20 fs used throughout. 
In all simulations, the temperature coupling was regulated using 
velocity rescale thermostat57, with the monolayer components 
(lipids, cholesterol, and SP-B1-25), water and ions, and AuNPs 
independently coupled to temperature baths at 310 K with time 
constants of 1 ps.  
Simulations were performed at a variety of AuNP 
concentrations and in different ensembles. Table 1 summarises 
the simulations that were performed. First, control systems 
(state 0) of DPPC:POPG:CHOL:SP-B1-25 monolayers were 
simulated in the absence of AuNPs in the NPγT (constant 
particle number, pressure, and temperature) ensemble at 
surface tensions of 0 and 23 mN/m, using Berendsen pressure 
barostat57, to reproduce the compressed and expanded states 
of the surfactant monolayer, respectively. The compressibility 
was set to 5 × 10!" bar-1 along the XY plane and 0 bar-1 along 
the Z-axis (such that the size of the simulation cell was fixed 
along with that dimension). In these control simulations, the 
area per lipid (APL) obtained after equilibration was 
0.470±0.001 and 0.538±0.001 nm2, for surface tensions of 0 and 
23 mN/m, respectively.  
The equilibrated control systems were then used as the 
initial configurations for the simulations of the monolayers in 
the presence of the AuNPs. The AuNPs were placed in vacuum 
space, close (< 1 nm, diameter) to the tails of the lipids in 
equilibrated monolayers. Systems were built at varying 
concentrations of AuNPs (~0.19, ~0.58, ~0.86, and ~1.53 mol% 
of AuNPs/lipids). The concentration modelled ranges from the 
lowest possible concentration (0.19 mol% of AuNPs/lipids - 
one 3 nm and one 5 nm AuNP) to the highest practicable 
concentration (1.53 mol% of AuNPs/lipids - eight 3 nm and 
eight 5 nm AuNPs) of polydisperse AuNPs for the size of our 
monolayer system. For each concentration of AuNPs, we 
account for polydispersity by having two different sizes (3 and 5 
nm) of AuNPs present. All systems contain an equal number of 
3 and 5 nm AuNPs. Due to computational constraints the size 
of the AuNPs modelled in the present work is at, or slightly 
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*I: Expanded, II: compressed, and III: re-expanded monolayer systems, poly.: polydisperse (mixed of 3 and 5 nm diameter AuNPs), mono.: monodisperse AuNPs 
below, the lower end of the size range of AuNPs considered in 
experimental studies. 9, 37, 38 
To study the effect of dispersity, we have simulated two 
monodisperse systems - consisting of 3 and 5 nm (diameter) 
AuNPs at a concentration of ~0.58 mol% of AuNPs/lipids (Table 
1).  All the systems containing AuNPs were simulated in the 
canonical (NVT) ensemble at either an APL of 0.54 (state I) or 
0.47 (state II) nm2, corresponding to the expanded and 
compressed states, respectively. Each system was first 
equilibrated for a further 100 ns before a 3 𝜇𝑠 production run.  
After the 3 𝜇𝑠 production runs at constant APL, the systems 
with polydisperse AuNPs at an APL of 0.47 nm2 were simulated 
for a further 3 𝜇𝑠 in the NPγT ensemble at a surface tension of 
23 mN/m (with the compressibility along XY plane and Z-axis set 
to 5 × 10!" and 0 bar-1, respectively). These systems, denoted 
as state III (re-expanded), were simulated in order to investigate 
the effects of AuNPs concentrations on LS monolayer breathing 
cycle, with the monolayers attempting to undergo a re-
expansion process.  
Analyses were carried out to compute different physical and 
dynamical properties of LS surfactant components with 
averages taken from over the last 1 𝜇𝑠 of each simulation. At 
least two repeat runs were performed for each system, and 
the analysis of properties averaged over the results of the 
repeat runs. All simulations snapshots were taken using the 
program Visual Molecular Dynamics (VMD).58 In VMD, a Tcl 
script59 (cg_bonds-v5.tcl) was used for rendering CG MARTINI 
bonds. PLs tails order parameters were determined using do-
order-gmx5.py python script.60 Full methodological details of 
the analyses are provided in the supporting information, section 
S1 “Methodological Details of Analyses”.  
3. Result and discussion 
3.1. Effects of SP-B1-25 and AuNPs on LS structure: 
3.1.1. Lung surfactant monolayer surface tension: 
LS components adsorb at the air-water interface in the form of 
a monolayer and regulate the surface tension at the interface. 
Therefore, it is anticipated that the surface tension remains 
unchanged/constant for the monolayer with a constant surface 
area until some external factors (e.g. the presence of airborne 
NPs) alter the surface tension value during breathing. We have 
shown previously12, 13 that bare monodisperse AuNPs increase 
the surfactant monolayer surface tension at the interface. In the 
current study, we consider the effect of AuNPs of different sizes 
as model NPs to quantify the role of airborne NPs on SP-B1-25 
containing LS monolayer in different states (I, II, and III). 
To quantify the impact of polydisperse AuNPs over 
monodisperse AuNPs on monolayer surface tensions, we have 
measured the surface tensions of the monolayers in the states 
I, (expanded, APL = 0.54 nm2) and II (compressed, APL=0.47 
nm2) in the presence of ~0.58 mol% AuNPs/lipids (Fig. 2). In the 
absence of any AuNPs, the surface tensions of the systems 
reproduce the physiological surface tensions that occur during 
the breathing process. However, in the presence of AuNPs, the 
surface tension increases significantly in both states (Fig. 2, 





No. of AuNPs 
(state, size) 
per monolayer  
Monolay
er State* 
Constant Variable Pore formation 
Surface 
tension  
/ mN m-1 
APL / 
nm2 
Surface tension  
/ mN m-1 
APL / nm2 
0 0 0 23   0.538±0.001 No 
0 0   0.470±0.001 No 
~0.19 2 (poly.) I  0.54 26.3±1.6  No 
II  0. 47 21.2±1.3  No 
III 23   0.475±0.006 No 
~0.58 6 (poly.) I  0.54 38.0±0.8  No 
II  0.47 31.2±0.7  No 
III 23   0.440±0.003 No 
6 (mono., 3nm) I  0.54 22.9±0.4  No 
II  0.47 22.3±2.7  No 
6 (mono., 5nm) I  0.54 44.2±0.4  No 
II  0.47 37.0±0.3  No 
~0.86 9 (poly.) I  0.54 41.2±2.0  No 
II  0.47 36.1±1.1  No 
III 23   0.429±0.009 No 
~1.53 16 (poly.) I  0.54 47.3± 1.0  Yes 
II  0.47 47.6±0.42  Yes 
III 23   0.426±0.004 Yes 
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Fig. 2 Comparison between the effects of the monodisperse and polydisperse AuNPs on 
the surface tensions for the monolayer in states I (APL= 0.54 nm2) and II (APL=0.47 nm2) 
at a concentration of ~0.58 mol% AuNPs/lipids. For the surface tension of monodisperse 
AuNPs, the average of the surface tensions of systems with 3 and 5 nm diameter AuNPs 
has been taken. The monolayer interfacial surface tension values of these two states (I 
and II) without any AuNPs are also presented. The error bars have been calculated using 
the standard deviation across repeated runs. 
We observe that polydisperse AuNPs result in a slightly higher 
surface tension value over averaged monodisperse AuNPs when 
the monolayer is in state I. However, the effect of polydispersity 
at ~0.58 mol% AuNPs/lipids appears to be 
marginal/insignificant on the surface tension of the monolayer 
in the state II. As the NP concentration increases, so does the 
surface tension for both states I and II, in agreement with the 
results of previous studies on monodisperse AuNPs12 (Table 1). 
It might be expected that the monolayer will be restored during 
the re-expansion process, state III, from the compressed state 
(state II). However, in state III the presence of AuNPs in the LS 
hindered the ability of the monolayer to return to a surface area 
of ~0.54 nm2, even at the lowest AuNP concentration. 
The presence of the surfactant peptide, SP-B1-25, in the LS 
monolayer containing no NPs has only a trivial effect on the 
monolayer interfacial surface tension, in line with the existing 
observations from previous studies in case of SP-B in the LS 
monolayer.27, 61, 62 We have investigated the effect of the 
presence of SP-B1-25 on the surface tension values of the 
monolayer in states I and II with the presence of ~0.86 mol% of 
monodisperse AuNPs/lipids (Table S1). The simulations predict 
that the presence of SP-B1-25 marginally reduces the surface 
tension of the monolayer in state II compared to a monolayer 
containing no SP-B1-25, but the surface tension slightly increases 
in the case of the monolayer in state I.   
3.1.2 Pore formation in the LS monolayer: 
Figure S2 shows representative snapshots of the LS monolayer 
in state II at different concentrations of AuNPs, both the 
aggregation of the NPs and the formation of pores are apparent. 
A higher concentration of NPs results in greater disruption to 
the LS monolayer and if the NP concentration is sufficiently high 
pores are formed in the LS. As the concentration of AuNPs in the 
monolayer increases, the more lipid molecules are adsorbed to 
the NPs’ surface, and this causes pores to be formed. Pores are 
observed at the AuNPs concentration of ≥1.53 mol% (Fig. S2d) 
for the polydisperse AuNPs (3 and 5 nm), whereas no pores in 
the monolayer are formed for ≤ 1.56 mol% of AuNPs/lipids for 
monodisperse AuNPs with diameter of 3 nm12, this difference is 
because of the total surface area of AuNPs is greater in the 
former than in the latter. Pores are also formed in the 
monolayer in other two states (I and III) (data not shown for 
brevity), which implies that pores formation does not depend 
on the monolayer breathing conditions/states. The formation of 
pores in the LS monolayer due to the presence of sufficient 
AuNP concentration agrees with an experimental study that 
reports cracks in the monolayer observed as AuNPs 
concentration is increased.38 Therefore, we believe that the 
formation of pores in the monolayer due to NP adsorption is 
representative of the true behaviour of the modelled systems. 
The formation of persistent pores in the LS monolayer can be a 
cause of serious health problems, including the hindrance of 
normal gas exchange process inside the alveoli and surfactant 
monolayer associated water level elevation.63, 64 As a result, the 
required oxygen cannot reach into the bloodstream and one 
could develop acute respiratory distress syndrome. Lipids 
adsorb to the NPs’ hydrophobic surface, which affects the 
packing of lipids in the monolayer. In the present study, the 
diameter of the AuNPs modelled (3 and 5 nm) is greater than 
the monolayer thickness (~2 nm). As a result, the adsorption of 
the lipids on AuNP surface results in the prevention of the 
exposure of the bare surface of the AuNPs to the vacuum 
and/or water phases. The same observation was previously 
found in a simulated study for the environmental hydrophobic 
carbon NP surface exposed to air.65 Radial distribution 
functions (RDF) of surfactant lipids (DPPC, POPG, CHOL and SP-
B1-25) to AuNPs 3 nm (Fig. S3a) and 5 nm (Fig. S3b) represent 
the preference of the surfactant lipids to the AuNPs surface. In 
both cases (3 and 5 nm), the cholesterol molecule has the 
greater interaction to AuNP than other two phospholipids 
(DPPC, POPG and SP-B1-25). The high preference of cholesterol 
molecules to AuNPs arises due to the hydrophobic-
hydrophobic interaction. 
In the present investigation, the simulations predict the 
aggregation of polydisperse AuNPs (vide infra), and the 
formation of a reverse micellar structure around of the AuNPs 
is observed (Fig. S4). The formation of the reverse micelles in 
the monolayers occurs as a result of some of the PLs orientating 
themselves with their headgroups directed away from the NP 
surface.  
In our previous study, we found an aggregation of the AuNPs 
in the monolayer12, and prior CGMD simulation studies have 
predicted that the adsorbed lipids form reverse micelles around 
the NPs, which can influence the aggregation of NPs within LS 
monolayers. 66 
3.1.3 Lung surfactant monolayer components’ density profiles: 
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To measure the effects of surfactant peptide (SP-B1-25) and 
polydispersity of AuNPs on the surfactant lipids density profiles, 
 
Fig. 3 (a) Lipid density profiles of LS monolayers in absence of AuNPs, for monolayers free of SP-B1-25 (green) and with SP-B1-25 present (red) at surface tensions (ST) of 23 (solid lines) 
and 0 mN/m (dashed lines). (b) Lipid density profiles for LS monolayers in the presence of AuNPs, for systems with monodisperse (green) and polydisperse (red) samples of AuNPs 
at an exemplar concentration of ~0.86 mol% of AuNPs/lipids for the monolayer in states I (solid lines), II (dashed lines), and III (red-dotted lines). Water density profiles (purple) were 
computed at surface tensions (a) 0 and (b) 23 mN/m.
we have computed the lipid (DPPC, POPG, CHOL) density 
profiles between the systems with and without SP-B1-25 (Fig. 3a) 
as well as between the systems with monodisperse and 
polydisperse AuNPs (Fig. 3b) at a concentration of ~0.86 mol% 
of AuNPs. Comparison of the peak heights of the lipid density 
profiles of the monolayers containing SP-B1-25 with monolayers 
where SP-B1-25 is absent indicates that the former has a slightly 
lower the peak height than the latter at both surface tensions 
(Fig. 3a). The result indicates that the surfactant monolayer-
associated peptides participate in decreasing lipid density 
profiles i.e., fluidizing the monolayer components, which is in 
reasonable agreement with previous in silico3 and in vitro67 
studies. At an AuNPs concentration of 0.86 mol%, there is a 
small reduction in the peak height of the lipid density profiles 
for the polydisperse systems over the monodisperse systems in 
states I and II (Fig. 3b). For the monolayers in state III (at a 
concentration of 0.86 mol% of AuNPs/lipids), the peak height of 
the density profiles of the lipids are slightly higher for the 
polydisperse system than the monodisperse one (Fig. 3b). 
During the simulation of the monolayers (all states) exposed to 
NPs (monodisperse/polydisperse), the NPs have lipids adsorbed 
to their surface, which induces long tails in the density profiles  
 (Fig. 3b) towards the water layer and thus decreases the height 
of the peak in the density profiles of the lipids from the control 
values (peak height of density profiles of lipids in the monolayer 
without NPs). The density profiles of the individual components 
of the surfactant monolayer (DPPC:POPG:CHOL:SP-B1-25)  and 
water have been plotted in Fig. S5 (insets: cholesterol and SP-
B1-25 densities for clarity) for the systems with the polydisperse 
AuNPs. The density profiles have been calculated for the 
monolayer in states I (Fig. S5a) and II (Fig. S5b). The AuNPs 
disrupt the orientation of the lipids, and thus the height of the 
peak in the density profile of each component of the LS 
monolayer is reduced compared to the control simulations. The 
density profile curves in Fig. S5 show that at the lowest 
concentrations AuNPs (~0.19-0.86 mol% of AuNPs/lipids) there 
is a negligible change in the LS density profiles, whereas the 
highest concentration ~1.53 mol% of AuNPs/lipids substantially 
changes the density profiles for each LS components. 
 The concentration effects of AuNPs are more significant in 
the state II systems than in the state I systems because lipids are 
more densely arranged in the monolayers in the state II than in 
the state I. The density profiles of cholesterol and SP-B1-25 follow 
a similar trend to the PLs density profiles for all concentrations 
of polydisperse AuNPs (Fig. S5 insets). 
3.1.4 Lung surfactant monolayer lipid ordering: 
Lipid order parameters provide information about the phase of 
the monolayer and fluctuations in the order parameter values 
can indicate that lipids are in a phase transition state. The lipids 
in the LC phase of a monolayer are highly ordered and exhibit 
high values of the order parameter unlike the lipids in a LE 
phase. However, the presence of NPs has a substantial impact 
on the lipid order parameter values. The order parameter of 
lipid tails decreased for all three states (Fig. 4 and Fig. S6), for 
both chains in the presence of the NPs. As the AuNP 
concentration increased, the order parameters decreased. The 
phenomena of lipid disordering is more noticeable in lipid chain 
1 (Fig. 4a, c and Fig. S6a) than chain 2 (Fig. 4b, d and Fig. S6b). 
The results, as shown in Fig. 4, indicate that the AuNPs disturb 
the lipids’ systematic arrangement in the monolayer and the 
high concentration of the NPs substantially changes the 
physiological ordering of the lipids in the monolayers. The 
presence of SP-B1-25 in the monolayer slightly decreases the 
ordering of both phospholipids (DPPC, POPG) tail beads (Fig. 
S7a, b) compared to a system without any surfactant proteins 
present. On the other hand, only marginal differences in order 
parameters for both lipid species were observed in case of 
polydispersed versus monodispersed AuNPs at a concentration 
~0.58 mol% of AuNPs/lipids in the monolayer in state II (Fig. S7c, 
d).  
3.1.5 Lung surfactant monolayer folding, SP-B1-25 cluster 
formation, and aggregation of AuNPs: 
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A CGMD study by Duncan et al.3 revealed that LS monolayer 
folding occurs when either the fold nucleates about a defect.   
 
Fig. 4 The effect of AuNPs concentrations on DPPC (solid lines) and POPG (dash lines) lipid tail order parameters, chain 1 (sn-1) in (a, c) and chain 2 (sn-2) in (b, d) of the monolayer 
in states I (a, b) and II (c, d). The ~0.19, ~0.58, ~0.86, and ~1.53 mol% concentrations of AuNPs/lipids are shown by the blue, yellow, green, and red lines respectively. The error bars 
have been calculated using the standard deviation across at least two repeat runs.
owing to the perturbation of the monolayer peptide SP-B1-25 or 
by the undulations of the monolayer. Our results also indicate 
that SP-B1-25 aggregates in the monolayer forming clusters of 
peptides, with a fold then nucleating at the site of this cluster 
(Fig. 5) in the NP free monolayer. A finding that agrees with the 
claims made by Duncan et al.3 In the monolayer, the positively 
charged peptide SP-B1-25 (5 positively charged residues) is found 
to adhere with the heads of the surfactant PLs (Fig. 5c). The 
preference of SP-B1-25 to the PLs head groups is because the 
surfactant PLs contain anionic lipid POPG (with a negative 
charge in the headgroup). This lends support to the previous in 
vitro findings.44, 68 These electrostatic interactions between the 
anionic POPG and cationic SP-B1-25 have been proposed to play 
a significant role in lamellar bodies (LB) formation, protein 
surface activities and aggregation in the LS monolayer.69  
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Fig. 5 Monolayer folding associated with the SP-B1-25 aggregation, for a monolayer at a surface tension of 0 mN/m: (a-b) two side views of the beginning of monolayer 
to bilayer transformation, and (c) snapshot showing the close correspondence of SP-B1-25 with the head groups of PLs. All the snapshots were taken during monolayer 
compression at surface tension 0 mN/m of the DPPC:POPG:CHOL:SP-B1-25 system, in the absence of NPs.
Experimentally, it has been demonstrated that LS monolayer 
compression has less influence in the SP-B clustering process, 
but the protein concentration in the monolayer is key in 
determining the size and number of protein clusters in the 
monolayer.70 To investigate the aggregation behaviour of SP-B1-
25, we performed a cluster analysis of the protein segments 
throughout the simulation (Fig S8a). Two or more peptides were 
assigned to the same cluster if the distance between them was 
≤ 1.2 nm. Initially, the SP-B1-25 molecules are well distributed in 
the monolayer, but by 2 µs every peptide is part of a cluster of 
at least two molecules. A representative snapshot (Fig. S8b) and 
2D map of the peptide density (Fig. S8c) confirm this 
aggregation behaviour and show how the peptide is distributed 
in the equilibrated (at surface tension 0 mN/m) monolayer. 
While SP-B1-25 aggregates even in the absence of NPs, the 
adsorption of NPs into the LS monolayer sharply increases the 
aggregation of the peptide. A plot showing the formation of 
clusters of SP-B1-25 in the presence of AuNPs is given for an 
exemplar system (state II, 0.19 mol% of AuNPs) in Fig. 6.  
The presence of the AuNPs increases the propensity of the 
peptide to aggregate in a monolayer, with the number of 
peptides present in the largest cluster higher than in the 
absence of any AuNPs (Fig. S8) even for systems with the lowest 
AuNP concentration (Fig. 6 and S9). Both the number of clusters 
and the number of peptides in the largest cluster stabilize more 
quickly in the presence of the hydrophobic AuNPs in state II (Fig. 
6) than in the case of state I (Fig S9) or in the monolayer in the 
absence of AuNPs (Fig. S8), indicating that the clusters are 
apparently more stable for monolayers with a lower surface 
area. In addition, the number of peptide clusters predicted in 
the monolayers in state II remain nearly unchanged during the 
expansion process of the monolayers in state III (Fig. S10). We 
hypothesise that the increased aggregation of SP-B1-25 in the 
presence of AuNPs is driven by a hydrophobic interaction 
between the two species. Ultimately, the clustering of the 
proteins in the LS monolayer coupled with the hydrophobic 
AuNPs presence in the monolayer may lead to lipoprotein 
corona formation on the NPs surface (Fig. S11).
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Fig. 6 (a) Cluster size analysis of surfactant peptide B (SP-B1-25) in state II (APL of ~0.47 nm2) with a AuNP concentration of ~0.19 mol% of AuNPs/lipids, simulation time is presented 
along X-axis, the number of SP-B1-25 in the largest cluster is presented along Y-axis, and the number of clusters is presented along Z-axis, (b) visualization of SP-B1-25 clustering in the 
surfactant monolayer (top view), and (c) SP-B1-25 number density map after 2 µs of simulation.
 
Fig. 7 Effects of SP-B1-25 on AuNP (~0.9 mol% of AuNPs/lipids) aggregation in LS 
monolayer in state II, in the presence (orange) and absence (blue) of SP-B1-25. The 
analyses have been performed over the full 3 µs of simulation.  
We have considered two systems to measure the role of SP-
B1-25 in AuNP clustering, one with and another one without SP-
B1-25, where each system contains 3 nm-sized monodisperse 
AuNPs at a concentration of ~0.9 mol% of AuNPs/lipids and 
each monolayer is in state II. In the presence of hydrophobic 
surfactant peptide SP-B1-25, the number of AuNPs clusters is 
decreased, and the number of AuNPs in the largest cluster is 
increased (Fig. 7). Therefore, we conclude that AuNPs and the 
SP-B1-25 peptide have a co-operative effect mutually increasing 
the propensity of both to aggregate. 
3.2 Effects of SP-B1-25 and AuNPs on LS PLs diffusion: 
To investigate the effect of the presence of SP-B1-25 on the 
lateral mobility of the PLs the 2-dimensional (2D) lateral mean-
square displacement (MSD) has been calculated for systems 
with and without SP-B1-25 (MSD calculation details have been 
provided in the ESI). In the presence of SP-B1-25, the diffusion of 
the PLs in the compressed monolayer is slightly increased (Fig. 
S12). This is because the hydrophobic peptide, SP-B1-25, fluidizes 
the LS monolayer3 and thus the PL MSD is greater in the 
monolayer with surfactant peptide over without peptide 
system. 
We have measured the PLs’ 2D MSD (Fig. S13 for state I) and 
lateral diffusion coefficients (Fig. S14) in all the three states (I, 
II, and III) of the surfactant monolayer at four different 
concentrations of AuNPs (~0.19, ~0.58, ~0.86, and ~1.53 mol% 
of AuNPs/lipids). The 2D MSD, and thus the lateral diffusion 
coefficients, of PLs in the monolayer significantly decrease with 
the increasing concentration of AuNPs present in the 
monolayer. We have observed that a drastic fall in the PL 
diffusion coefficient with the increase of AuNPs concentration 
from 0.19 to 0.58 mol% for monolayers in states II and III. We 
propose that this is because of the adsorption of PLs to the NPs’ 
surface and subsequent formation of clusters of NPs (vide 
supra) hinders the ability of the PLs to diffuse. The PLs 
adsorption on the NP surfaces and subsequent formation of 
nano-clusters is promoted due to the decrease of the PLs free 
space in the monolayer with an increased volume of AuNPs. 
The diffusion of PLs in the LS monolayers (state II) exposed 
to polydisperse AuNPs is lower compared to the monodisperse 
AuNPs (3 and 5 nm) at a concentration of ~0.58 mol% of 
AuNPs/lipids (Fig. S15). This result is due to the fact that the 
total AuNP surface area is greater for the polydisperse and 
monodisperse AuNPs (5 nm) systems than the monodisperse 
system with 3 nm AuNPs, and so, more lipids are able to adsorb 
to the AuNPs surface, thus reducing the rate of diffusion of PLs.  
Conclusions 
The adsorption of polydisperse samples of AuNPs to LS 
monolayer containing a hydrophobic peptide have been 
modelled for three different breathing cycles using CGMD 
simulations. The presence of the peptide (SP-B1-25) and NPs in 
the LS monolayer mutually promote the aggregation of both 
species via hydrophobic interaction. In addition, the 
hydrophobic properties of the NPs, SP-B1-25, and the tails of the 
surfactant lipids induce an interaction between the surfactant 
molecules and the NPs, which could lead to lipoprotein corona 
formation. As a result, the biophysical functions of the LS 
monolayer in expanded, compressed and re-expanded states 
could be hampered. It is found that despite an attempted re-
expansion process LS monolayers which have NPs embedded 
within them are unable to achieve a surface area similar to NP 
free monolayers. Furthermore, the AuNP concentration 
markedly affects the diffusion of the PLs process because of the 
PLs adsorption to the NPs’ surface. The current study has 
identified that the levels of NP polydispersity considered in this 
study have a significant role, but limited effect on the behaviour 
of LS monolayers. The insights gained from this study will be of 
assistance to understand the NPs contribution on monolayer 
pore formation, a contributor to lung diseases. The findings of 
these model simulations will assist the nanotechnologists, 
biophysicist, and pharmacist to model nanomedicine for lung 
area in future.  
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